



BOSTON COMMERCE LIMITED
(Formerly known as Boston Bio Systems Limited)
Registered office: A.828, Sun West Bank, Ashram Road P.O, Ahmedabad,
City Taluka, Gujarat, India, 380009
CIN: L62013GJ1995PLC025476; E-mail: bostonsystem@yahoo.com
Website: www.bostonbio.in

Date: July 13, 2026

To,
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400001

Scrip Code: 531458
Symbol: BOSTON

Subject: Outcome of the Adjourned Meeting of the Board of Directors held on 13th July, 2026 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Adjourned Meeting of the Board of Directors of Boston Commerce Limited was held today, i.e., Monday, 13th July, 2026, at the Registered Office of the Company. The meeting commenced at 6:00 p.m. and concluded at 6:56 p.m.

The Board of Directors, inter alia, considered and approved the following:

1. The Board considered and approved, subject to the approval of the Members by way of a Special Resolution at the ensuing Extraordinary General Meeting and such other statutory and regulatory approvals as may be required, the proposal to borrow monies, including by way of inter-corporate loans and other permissible borrowings, up to an aggregate amount of ₹100 Crores for each financial year up to and including the Financial Year 2028-29, in accordance with the applicable provisions of the Companies Act, 2013 and other applicable laws. **(As annexed in Annexure I)**
2. The Board considered and approved, subject to the approval of the Members by way of a Special Resolution at the ensuing Extraordinary General Meeting and such other statutory and regulatory approvals as may be required, the proposal to authorize the Board of Directors to evaluate, negotiate, finalize and undertake acquisition of ongoing businesses, business undertakings, business units and strategic business assets, from time to time, up to an aggregate investment amount of ₹100 Crores for each financial year up to and including the Financial Year 2028-29, subject to applicable provisions of the Companies Act, 2013, SEBI Regulations and other applicable laws. **(As annexed in Annexure II)**
3. The Board considered and approved the updating of the list of authorised signatories for the Company's bank accounts and other statutory, financial and operational records in accordance with the present composition of the Board of Directors. **(As annexed in Annexure III)**



4. The Board considered and approved, the proposal to evaluate and undertake monetisation, restructuring or disposal of the Company's non-income generating assets and non-core assets, subject to applicable laws and necessary approvals.
The Board further authorised the Managing Director/Chief Financial Officer/authorised representatives of the Company to take all necessary steps, negotiate, execute documents and undertake all acts, deeds and things as may be required to give effect to the aforesaid proposal. **(As annexed in Annexure IV)**
5. The Board considered and approved, subject to the approval of the Members by way of a Special Resolution at the ensuing Extraordinary General Meeting and such other statutory approvals, permissions and filings as may be required, the adoption of a new set of Memorandum of Association ("MOA") and Articles of Association ("AOA") of the Company in substitution of the existing MOA and AOA, to align the constitutional documents of the Company with the applicable provisions of the Companies Act, 2013 and other applicable laws, as amended from time to time. **(As annexed in Annexure V)**
6. The Board considered and approved the appointment of Accurate Securities and Registry Private Limited as the Registrar and Share Transfer Agent ("RTA") of the Company in place of Adroit Corporate Services Private Limited, subject to obtaining the necessary statutory and regulatory approvals.
The Board also authorised the Managing Director, Company Secretary and other authorised officials to complete all necessary formalities and filings to give effect to the aforesaid appointment. **(As annexed in Annexure VI)**
7. The Board noted that the request received from the Promoter(s) seeking reclassification from the Promoter Category to the Public Category under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, contained certain deficiencies/incomplete information. Accordingly, the agenda item was not taken up for consideration, and no decision was taken by the Board in this regard. The matter shall be considered upon receipt of a complete and compliant request.

The Board authorised the Directors and Company Secretary of the Company to undertake all necessary actions, filings, disclosures and compliances in this regard.

Kindly take the above information on record.

Thanking You.

For and on behalf of

Boston Commerce Limited

(Formerly known as Boston Bio Systems Limited)

Ghanshyam Dhananjay Gavali

Managing Director

DIN : 03343352



BOSTON COMMERCE LIMITED
(Formerly known as Boston Bio Systems Limited)
Registered office: A.828, Sun West Bank, Ashram Road P.O, Ahmedabad,
City Taluka, Gujarat, India, 380009
CIN: L62013GJ1995PLC025476; E-mail: bostonsystem@yahoo.com
Website: www.bostonbio.in

Annexure I

Details pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of Approval for Raising Funds by way of Inter-Corporate Loans, Borrowings and Advances

Particulars	Disclosure
Nature of transaction	Approval for borrowing monies including inter-corporate loans and other permissible borrowings
Maximum borrowing limit	Up to an aggregate amount of ₹100 Crores for each financial year up to and including Financial Year 2028-29
Mode of borrowing	Inter-corporate loans, term loans, working capital facilities, non-convertible instruments and such other permissible borrowings
Purpose	To meet business expansion, acquisitions, investments, working capital requirements and other corporate purposes
Approvals required	Approval of Members by way of Special Resolution and such other statutory/regulatory approvals as may be applicable
Effective date	Subject to shareholders' approval and completion of applicable formalities



BOSTON COMMERCE LIMITED
(Formerly known as Boston Bio Systems Limited)
Registered office: A.828, Sun West Bank, Ashram Road P.O, Ahmedabad,
City Taluka, Gujarat, India, 380009
CIN: L62013GJ1995PLC025476; E-mail: bostonsystem@yahoo.com
Website: www.bostonbio.in

Annexure II

Disclosure for Proposed Acquisition Authority under Regulation 30 of SEBI (LODR) Regulations, 2015

Particulars	Disclosure
Nature of proposal	Authority to evaluate, negotiate and undertake acquisition of businesses/business undertakings/business units/strategic business assets
Aggregate investment limit	Up to ₹100 Crores for each financial year up to and including FY 2028-29
Objective	Expansion of business operations, diversification, strategic growth and value creation
Consideration	Cash, securities or any other permissible mode, as may be approved from time to time
Approvals required	Approval of Members by way of Special Resolution and other statutory/regulatory approvals, wherever applicable
Target entities	To be identified by the Board from time to time
Time period	Up to Financial Year 2028-29



BOSTON COMMERCE LIMITED
(Formerly known as Boston Bio Systems Limited)
Registered office: A.828, Sun West Bank, Ashram Road P.O, Ahmedabad,
City Taluka, Gujarat, India, 380009
CIN: L62013GJ1995PLC025476; E-mail: bostonsystem@yahoo.com
Website: www.bostonbio.in

Annexure III

Disclosure regarding Updating of Authorised Signatories

Particulars	Disclosure
Nature of approval	Updating of authorised signatories for the Company's bank accounts and statutory, financial and operational records.
Existing signatories	As per the existing mandates maintained with the respective authorities/banks.
Revised authorised signatories	Ms. Jansi Falgunkumar Patel, Director of the Company and Ms. Gunjan Jyotishbhai Leuva, Director of the Company .
Effective date	With immediate effect or upon completion of the necessary formalities with the respective banks and authorities.
Purpose	To align the authorised signatories with the present composition of the Board of Directors and Key Managerial Personnel.



BOSTON COMMERCE LIMITED
(Formerly known as Boston Bio Systems Limited)
Registered office: A.828, Sun West Bank, Ashram Road P.O, Ahmedabad,
City Taluka, Gujarat, India, 380009
CIN: L62013GJ1995PLC025476; E-mail: bostonsystem@yahoo.com
Website: www.bostonbio.in

Annexure IV

Disclosure regarding Monetisation / Restructuring / Disposal of Non-Core Assets

Particulars	Disclosure
Nature of proposal	Evaluation and undertaking of monetisation, restructuring or disposal of non-income generating assets and non-core assets
Objective	Efficient capital allocation, unlocking shareholder value and optimisation of business resources
Assets covered	Non-core assets and non-income generating assets of the Company
Consideration	To be determined based on valuation and commercial negotiations
Approvals	Subject to applicable provisions of the Companies Act, 2013, SEBI Regulations and other applicable laws, and such approvals as may be required
Authorised officials	Managing Director, Chief Financial Officer and authorised representatives of the Company
Timeline	As may be determined by the Board from time to time



BOSTON COMMERCE LIMITED
(Formerly known as Boston Bio Systems Limited)
Registered office: A.828, Sun West Bank, Ashram Road P.O, Ahmedabad,
City Taluka, Gujarat, India, 380009
CIN: L62013GJ1995PLC025476; E-mail: bostonsystem@yahoo.com
Website: www.bostonbio.in

Annexure V

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Particulars	Disclosure
Nature of approval	Approval of the proposal to adopt a new set of Memorandum of Association ("MOA") and Articles of Association ("AOA") of the Company.
Reason for adoption	To align the constitutional documents of the Company with the provisions of the Companies Act, 2013, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws, rules and regulations, as amended from time to time, and to incorporate necessary modifications for improved governance and operational flexibility.
Existing documents	Existing Memorandum of Association and Articles of Association of the Company.
Proposed documents	New set of Memorandum of Association and Articles of Association to be adopted in substitution of the existing MOA and AOA.
Effective date	Subject to approval of the Members by way of a Special Resolution at the ensuing Extraordinary General Meeting and filing of the necessary forms with the Registrar of Companies.
Regulatory approvals	Approval of the Members and such other statutory approvals, permissions and filings as may be required.



BOSTON COMMERCE LIMITED
(Formerly known as Boston Bio Systems Limited)
Registered office: A.828, Sun West Bank, Ashram Road P.O, Ahmedabad,
City Taluka, Gujarat, India, 380009
CIN: L62013GJ1995PLC025476; E-mail: bostonsystem@yahoo.com
Website: www.bostonbio.in

Annexure VI

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Particulars	Disclosure
Reason for change	Appointment of a new Registrar and Share Transfer Agent ("RTA") in place of the existing RTA.
Name of Existing RTA	Adroit Corporate Services Private Limited
Name of Proposed RTA	Accurate Securities and Registry Private Limited
Reason for Appointment	To streamline and strengthen the Company's registrar and share transfer services and enhance operational efficiency.
Effective Date	Subject to obtaining the necessary statutory and regulatory approvals and completion of all applicable formalities.
Brief Profile of the Proposed RTA	Accurate Securities Limited is a SEBI-registered Registrar to an Issue and Share Transfer Agent providing registry and share transfer services to listed and unlisted companies in accordance with applicable laws and SEBI regulations.